Erdafitinib (JNJ-42756493)

Name: Erdafitinib (JNJ-42756493); MyBioSource
Brand: MyBioSource
SKU: MBS3601392
Price: 220 USD
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS3601392

Erdafitinib (JNJ-42756493) is a highly potent and selective, small-molecule inhibitor of FGFR family. More details

$220 / 5 mg +1 FREE 8GB USB

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Erdafitinib, Biochemical

Full Product Name

Erdafitinib

Product Synonym Names

JNJ-42756493

Purity/Purification

>98% (HPLC)

Preparation and Storage

Store at -20 degree C
Stability: >=2 years
Shipping: Ice Pack

Molecular Weight

446.5447

Suitability

DMSO: >=33mg/mL

Target

FGFR

Receptor

FGFR1; FGFR2; FGFR3; FGFR4

Chemical Name

1, 2-Ethanediamine, N1-(3, 5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]

SMILES

CC(NCCN(C1=CC(OC)=CC(OC)=C1)C2=CC=C3N=CC(C4=CN(C)N=C4)=NC3=C2)C

Molecular Formula

C25H30N6O2

CAS Number

1346242-81-6

Product Categories/Family for Erdafitinib biochemical

Blood cancer; Angiogenesis; Cancer

Product References and Citations for Erdafitinib biochemical

1. Perera TPS, et al. Mol Cancer Ther. 2017 Jun; 16 (6):1010-1020.
2. Karkera JD, et al. Mol Cancer Ther. 2017 Apr 17. pii: molcanther.0518.2016.
3. Verstraete M, et al. BMC Cancer. 2015 Dec 16; 15:946.

Other Notes

Small volumes of Erdafitinib biochemical vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Erdafitinib purchase

MBS3601392 is a biochemical targeting Erdafitinib.